Cardiopulmonary Bypass Induced Red Blood Cell Lysis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-88
SponsorUniversity of Maryland, Baltimore

About this trial

Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.

Eligibility criteria

Qualifiers

Admitted to UMMC for cardiac procedure

Age: >/=18 y.o TO 88 y.o.

Undergoing CPB >1hr for the following surgeries (a) complex cardiac surgery (b) heart valve replacement surgery OR (c) CABG surgery.

Disqualifiers

Pregnant

Non English speaking

Unable to consent or have Legally Authorized Representative (LAR) assent to study

Trial design

Treatments tested in this trial

  • Blood and urine collection

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Maryland, Baltimore

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator